Ocular neovascularization: a valuable model system

被引:85
作者
Campochiaro, PA
Hackett, SF
机构
[1] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA
关键词
VEGF; angiogenesis; angiopoietins; retinopathies; age-related macular degeneration;
D O I
10.1038/sj.onc.1206773
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is no unique formula for angiogenesis. Instead there is a large group of potential participating proteins that interact in complex ways. Depending upon the surrounding cell types and the relative expression levels of angiogenesis-related proteins, the 'angiogenesis cascade' can vary. Therefore, it is valuable to study and compare the role of proteins in several well-characterized vascular beds. The eye provides a useful model system, because it contains several vascular beds sandwiched between avascular tissue. This allows for unequivocal identification and quantitation of new vessels. Retina-specific promoters combined with inducible promoter systems provide a means to regulate the expression of proteins of interest. As a relatively isolated compartment, the eye also provides advantages for gene transfer. By gaining insight regarding the molecular signals involved in various types of ocular angiogenesis, general concepts can emerge that may apply to other settings, including tumor angiogenesis. One concept that has emerged is that despite participation of multiple stimulatory factors for ocular neovascularization, VEGF plays an essential role and interruption of VEGF signaling is an important therapeutic strategy. Another concept is that while most studies have focused on prevention of ocular neovascularization, regression of new vessels is desirable and is achievable with at least three agents, combretastatin A-4 phosphate, pigment epithelium-derived factor, and angiopoietin-2. Finally, endostatin and angiostatin, which have been sources of controversy because of inconsistent results in tumor models, have been shown to have good efficacy when delivered by gene transfer in models of ocular neovascularization. These results provide leads for new ocular treatments and perspective for evaluation of studies of neovascularization in extraocular tissues.
引用
收藏
页码:6537 / 6548
页数:12
相关论文
共 134 条
[71]   Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin [J].
Mori, K ;
Ando, A ;
Gehlbach, P ;
Nesbitt, D ;
Takahashi, K ;
Goldsteen, D ;
Penn, M ;
Chen, CT ;
Mori, K ;
Melia, M ;
Phipps, S ;
Moffat, D ;
Brazzell, K ;
Liau, G ;
Dixon, KH ;
Campochiaro, PA .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (01) :313-320
[72]  
NAMBU H, 2003, IN PRESS INVEST OPHT
[73]   Vascular endothelial growth factor expression is increased in renal cell carcinoma [J].
Nicol, D ;
Hii, SI ;
Walsh, M ;
Teh, B ;
Thompson, L ;
Kennett, C ;
Gotley, D .
JOURNAL OF UROLOGY, 1997, 157 (04) :1482-1486
[74]   Antiangiogenic activity of the cleaved conformation of the serpin antithrombin [J].
O'Reilly, MS ;
Pirie-Shepherd, S ;
Lane, WS ;
Folkman, J .
SCIENCE, 1999, 285 (5435) :1926-1928
[75]   Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment [J].
Ohno-Matsui, K ;
Hirose, A ;
Yamamoto, S ;
Saikia, J ;
Okamoto, N ;
Gehlbach, P ;
Duh, EJ ;
Hackett, S ;
Chang, M ;
Bok, D ;
Zack, DJ ;
Campochiaro, PA .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (02) :711-719
[76]  
Okamoto N, 1997, AM J PATHOL, V151, P281
[77]   Vascular endothelial growth factor B, a novel growth factor for endothelial cells [J].
Olofsson, B ;
Pajusola, K ;
Kaipainen, A ;
vonEuler, G ;
Joukov, V ;
Saksela, O ;
Orpana, A ;
Petersson, RF ;
Alitalo, K ;
Eriksson, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) :2576-2581
[78]   ANGIOSTATIN - A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG-CARCINOMA [J].
OREILLY, MS ;
HOLMGREN, L ;
SHING, Y ;
CHEN, C ;
ROSENTHAL, RA ;
MOSES, M ;
LANE, WS ;
CAO, YH ;
SAGE, EH ;
FOLKMAN, J .
CELL, 1994, 79 (02) :315-328
[79]   Endostatin: An endogenous inhibitor of angiogenesis and tumor growth [J].
OReilly, MS ;
Boehm, T ;
Shing, Y ;
Fukai, N ;
Vasios, G ;
Lane, WS ;
Flynn, E ;
Birkhead, JR ;
Olsen, BR ;
Folkman, J .
CELL, 1997, 88 (02) :277-285
[80]  
OSHIMA Y, 2003, UNPUB DIFFERENT EFFE